2025年10月29日至11月12日,主要股东Ansbert Gadicke出售狼人治疗(HOWL)649K股,净额为771K,将其股份减少到5.69M股。 Major shareholder Ansbert Gadicke sold ~649K shares of Werewolf Therapeutics (HOWL) Oct 29–Nov 12, 2025, netting $771K, reducing his stake to ~5.69M shares.

在2025年10月29日至11月12日期间,主要股东Ansbert Gadicke出售了约649 000股狼人治疗药物(HOWL),产生约771 000美元的收益。 Major shareholder Ansbert Gadicke sold approximately 649,000 shares of Werewolf Therapeutics (HOWL) between October 29 and November 12, 2025, generating around $771,000 in proceeds. 在证交会申报中披露的销售量,将他的股份减少了约0.7%,达到约569万股。 The sales, disclosed in SEC filings, reduced his stake by about 0.7% to roughly 5.69 million shares. 该公司报告的季度损失为每股0.36美元,略高于预期。 The company reported a quarterly loss of $0.36 per share, slightly better than expected. 11月13日股票交易额为0.98美元,市场最高限额为4 733万美元。 Shares traded at $0.98 on November 13, with a market cap of $47.33 million. 分析师对此评价不同, 普遍认为"适度购买"和目标价8美元. Analysts have mixed ratings, with a consensus "moderate buy" and a $8.00 target price.